CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines
Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
Advertisement
CureVac N.V. and The University of Texas MD Anderson cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.
“We look forward to collaborating with the team at MD Anderson to push the boundaries of mRNA technology and develop impactful therapeutic options for patients in need,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. “In combining our respective expertise, we believe we can go further and faster to develop novel, off-the-shelf, mRNA-based cancer vaccines that have the potential to significantly improve patient outcomes.”
Both parties will contribute to the identification of differentiated cancer antigens based on whole genome sequencing, combined with long- and short-read RNA sequencing and cutting-edge bioinformatics. Joint preclinical validation of the highest-quality cancer antigens will be supported by Sachet Shukla, Ph.D., Assistant Professor of Hematopoietic Biology & Malignancy and director of the department’s cancer vaccine program, and by MD Anderson’s ECLIPSE (Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant) platform, part of the institution’s Therapeutics Discovery division.
“We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,” Shukla said. “This collaboration with CureVac is an important milestone in our efforts and brings together complementary strengths toward our goal of developing transformative vaccines for cancer.”
Following selection of the most promising validated vaccine candidates and completion of Investigational New Drug (IND) approvals, MD Anderson will be responsible for conducting initial Phase 1/2 studies in appropriate clinical indications.
“Our ECLIPSE team uses proprietary high-throughput technology to identify and validate immune targets, and we are driven to advance impactful immunotherapies with the potential to transform the lives of patients with cancer,” said Jeffrey Molldrem, M.D., chair of Hematopoietic Biology and Malignancy and leader of the ECLIPSE platform at MD Anderson. “Together with CureVac, we hope to embrace this exciting area of drug discovery and development in pursuit of mRNA vaccines that will address significant unmet medical need.”
Under the terms of the collaboration agreement, CureVac and MD Anderson will jointly contribute to and support development of those programs designated to move forward. CureVac has worldwide exclusive rights to late-stage development, commercialization, or partnering of the cancer vaccine candidates. MD Anderson is eligible for certain downstream payments based on potential future commercialization.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma - First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years
Siegfried opens new global R&D Center for Drug Substances in Evionnaz - New facility to drive development excellence and further growth
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery - First successful simultaneous 10-target multiplex-screening
BioMed X Institute launches new cancer collaboration with Daiichi Sankyo - Call for proposals from researchers around the world to take part in this ambitious project
CureVac enters clinical phase with mRNA vaccine - First data expected on intramuscular application of the newly developed vaccine
New drug candidates reverse drug resistance in multiple myeloma in preclinical models
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
NIH clinical trial of remdesivir to treat COVID-19 begins
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease
